Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of oral selpercatinib in advanced RET‑altered solid tumors
jRCT2051220060Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of selpercatinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC) and 4 more (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum tolerated dose / recommended phase 2 dose in Japan and Objective response rate (IRC, RECIST 1.1 or RANO). Started Jul 2018; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)poorly differentiated thyroid carcinoma (PDTC)pheochromocytoma
Beyond the preview
Go deeper on jRCT2051220060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220060.